Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLP-1 receptor agonists improvement of constitution in overweight and obese patients with T2DM
ChiCTR-IPR-17010825Phase 4Recruiting
- Sponsor
- Xinqiao Hospital
- Start
- Mar 2017
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4 trial of exenatide in type 2 diabetes mellitus (T2DM), obesity and Overweight (2 arms), sponsored by Xinqiao Hospital. Primary endpoints: Body fat content, Visceral fat area and 4 more. Started Mar 2017; status: recruiting.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)obesityOverweight
Beyond the preview
Go deeper on ChiCTR-IPR-17010825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17010825.